Archon Capital Management LLC purchased a new position in shares of Histogenics Corp (NASDAQ:HSGX) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 232,318 shares of the biotechnology company’s stock, valued at approximately $639,000. Histogenics makes up 0.1% of Archon Capital Management LLC’s holdings, making the stock its 20th largest holding. Archon Capital Management LLC owned about 0.81% of Histogenics as of its most recent SEC filing.
Other large investors also recently made changes to their positions in the company. Virtu Financial LLC increased its holdings in Histogenics by 413.4% in the fourth quarter. Virtu Financial LLC now owns 63,563 shares of the biotechnology company’s stock valued at $130,000 after purchasing an additional 51,182 shares during the period. Deutsche Bank AG grew its holdings in Histogenics by 71.1% during the 4th quarter. Deutsche Bank AG now owns 71,706 shares of the biotechnology company’s stock worth $146,000 after acquiring an additional 29,806 shares during the period. Bradley Foster & Sargent Inc. CT acquired a new stake in Histogenics during the 1st quarter worth about $199,000. JPMorgan Chase & Co. acquired a new stake in Histogenics during the 1st quarter worth about $320,000. Finally, Renaissance Technologies LLC grew its holdings in Histogenics by 54.8% during the 4th quarter. Renaissance Technologies LLC now owns 242,500 shares of the biotechnology company’s stock worth $497,000 after acquiring an additional 85,800 shares during the period. Institutional investors own 53.51% of the company’s stock.
HSGX has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded Histogenics from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. ValuEngine downgraded Histogenics from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $4.00 price target on shares of Histogenics in a report on Monday, March 19th.
Shares of Histogenics traded up $0.16, reaching $2.88, on Thursday, Marketbeat Ratings reports. 101,700 shares of the company were exchanged, compared to its average volume of 106,370. The stock has a market capitalization of $79.18 million, a PE ratio of -2.94 and a beta of 1.63. Histogenics Corp has a one year low of $1.60 and a one year high of $3.35.
Histogenics (NASDAQ:HSGX) last released its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.45). research analysts forecast that Histogenics Corp will post -0.53 EPS for the current year.
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.